| __timestamp | Gilead Sciences, Inc. | Neurocrine Biosciences, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2983000000 | 17986000 |
| Thursday, January 1, 2015 | 3426000000 | 32480000 |
| Friday, January 1, 2016 | 3398000000 | 68081000 |
| Sunday, January 1, 2017 | 3878000000 | 169906000 |
| Monday, January 1, 2018 | 4056000000 | 248932000 |
| Tuesday, January 1, 2019 | 4381000000 | 354100000 |
| Wednesday, January 1, 2020 | 5151000000 | 433300000 |
| Friday, January 1, 2021 | 5246000000 | 583300000 |
| Saturday, January 1, 2022 | 5673000000 | 752700000 |
| Sunday, January 1, 2023 | 6090000000 | 887600000 |
| Monday, January 1, 2024 | 6091000000 | 1007200000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding the financial strategies of leading companies is crucial. Over the past decade, Gilead Sciences, Inc. and Neurocrine Biosciences, Inc. have demonstrated contrasting approaches in managing their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Gilead Sciences consistently outpaced Neurocrine Biosciences, with SG&A expenses growing from approximately $3 billion to over $6 billion, marking a 104% increase. In contrast, Neurocrine Biosciences started with a modest $18 million in 2014, escalating to nearly $888 million by 2023, a staggering 4,800% rise. This disparity highlights Gilead's established market presence and Neurocrine's aggressive growth strategy. As these companies navigate the competitive landscape, their financial decisions will continue to shape their trajectories and influence the broader industry.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Neurocrine Biosciences, Inc.
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Breaking Down SG&A Expenses: Gilead Sciences, Inc. vs Axsome Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Gilead Sciences, Inc. and Opthea Limited
Selling, General, and Administrative Costs: Gilead Sciences, Inc. vs Xenon Pharmaceuticals Inc.
Breaking Down SG&A Expenses: Alnylam Pharmaceuticals, Inc. vs Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. and Summit Therapeutics Inc.: SG&A Spending Patterns Compared
Neurocrine Biosciences, Inc. vs Walgreens Boots Alliance, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Alkermes plc
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. and Wave Life Sciences Ltd.: SG&A Spending Patterns Compared